dabrafenib + trametinib + cetuximab + panitumumab + oxaliplatin + irinotecan + leucovorin + 5-fluorouracil

This is an **8-drug combination regimen** comprising the following agents:\n- **dabrafenib** (a BRAF inhibitor, small molecule),\n- **trametinib** (a MEK inhibitor, small molecule),\n- **cetuximab** and **panitumumab** (both EGFR-targeting monoclonal antibodies, usually used alternatively, not simultaneously, in regimens),\n- **oxaliplatin** and **irinotecan** (cytotoxic chemotherapies: platinum compound and topoisomerase I inhibitor, respectively),\n- **leucovorin** (folinic acid, biochemical modulator enhancing 5-fluorouracil activity),\n- **5-fluorouracil** (antimetabolite cytotoxic agent).\nThese drugs are used in combination primarily for the **treatment of metastatic colorectal cancer with BRAF mutations**, especially in the second-line setting. The combination targets multiple pathways associated with cancer cell growth and survival, including BRAF, MEK, EGFR, DNA replication, and is intended to overcome resistance mechanisms to single-agent targeted therapies. The combined use of these agents reflects a strategy to maximize antitumor activity through both targeted and cytotoxic approaches[1][2][3][4].

Brand names

Adrucil

Other names

dabrafenibtrametinibcetuximabpanitumumaboxaliplatinirinotecanleucovorin5-FU